Article Sidebar

pdf
Date Published: 25/09/2023
Online Published: 25/09/2023
Abstract Views: 91
Views pdf: 62
DOI: https://doi.org/10.55046/vjrnm.52.962.2023
Issue
No. 52 (2023)
Section
Scientific research
How to Cite
Tran, T. D. (2023). Evaluate the effectiveness of recurent lymph node dissection in differentiated thyroid cancer patient after 131I treatment at the Military Institute of Medical Radiology and Oncology. Vietnamese Journal of Radiology and Nuclear Medicine, 52, 32-38. https://doi.org/10.55046/vjrnm.52.962.2023

Evaluate the effectiveness of recurent lymph node dissection in differentiated thyroid cancer patient after 131I treatment at the Military Institute of Medical Radiology and Oncology

Tran Trong Dong1,
1 Military Institute of Radiation and Oncology Medicine

Main Article Content

Abstract

Objectives: to describe the clinical and subclinical symptoms and evaluate the response after recurrent lymph node dissection of differentiated thyroid cancer patients after 131I treatment.


Subjects: 50 differentiated thyroid cancer patients after 131I treatment, recurrence for the first time. Study methods: Retrospective and prospective description, data collection through patients’ medical records.


Results: the mean age of the study patients was: 43.5 ± 12.6, the most common age is <55 years old with the rate of 80%, the female/ male ratio=3.5/1. The group of patients with Tg < 1 ng/ml accounted for the majority with 33/50 patients (66%). The median Tg before and after surgery was 2.02 ng/ml and 0.35 ng/ml, respectively. After surgery, response achieved in 98% of patients, mainly complete response and incomplete response in biochemical, accounted for 40%, 36%. Lymph node dissection reduced Tg in 78% of patients. Reccurent lymph nodes mainly observed in group IV, group III and group VI. The recurrence of lymph nodes was mainly in the central and cervical regions on the same side of the primary tumor.


Conclusion: Surgery is the preferred first-line treatment for the reccurrent lymph node thyroid cancer patients. It changes response assessment, improve prognosis for reccurence patients after 131I treatment.

Article Details

Keywords

Differentiated thyroid cancer, response after recurrent lymph node dissection, Tg

References

1. Naoki Otsuki, Hikari Shimoda, Naruhiko Morita, et al. (2020), “Salvage surgery for structural local recurrence of papillary thyroid cancer: recurrence patterns and surgical outcome”, Endocr J 67(9), 949-956.
2. Laura Y. Wang (2018), “Post treatment surveillance of thyroid cancer”, European Journal of Surgical Oncology, 7983(17), 30588-30587.
3. Nguyễn Thị Lan Hương, Nguyễn Hữu Nghĩa, Lê Ngọc Hà, et al. (2021), “Nghiên cứu đặc điểm lâm sàng, cận lâm sàng của bệnh nhân ung thư tuyến giáp biệt hóa kháng 131I”, Tạp chí Y dược lâm sàng 108, 16.
4. Dương Chí Thành (2017), “Đánh giá kết quả điều trị ung thư tuyến giáp tái phát tại bệnh viện Đại học y Hà Nội”, Luận văn tốt nghiệp bác sĩ nội trú trường Đại học y Hà Nội- chuyên ngành ung thư.
5. Trần Ngọc Hải ( 2004), “Nghiên cứu đặc điểm lâm sàng, cận lâm sàng và kết quả điều trị của bệnh ung thư giáp trạng tái phát tại bệnh viện K, Đại học Y Hà Nội, Hà Nội.”.
6. Haugen B.R., Alexander E.K., Bible K.C, et al. (2016), “2015 American Thyroid Association Management Guidelines for AdultPatients with Thyroid Nodules and Differentiated Thyroid Cancer”, Thyroid, (26), 1-133.
7. “American Joint Committee on Cancer 8th (2017). Thyroid - Differentiated and Anaplastic Carcinoma”, 873-901.
8. Amblessed E. Onuma, Eliza W. Beal, Fadi Nabhan, et al. (2019), “Long-Term Efficacy of Lymph Node Reoperation for Persistent Papillary Thyroid Cancer: 13-Year Follow-Up”, Ann Surg Oncol, 26(6): , pp. 1737–1743